Streetbeat News

Price Targets

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Genmab (NASDAQ:GMAB) but lowers the price target from $51 to $49.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:17 pm

XPOF

Raymond James analyst Joseph Altobello has maintained a 'Strong Buy' rating on Xponential Fitness (NYSE:XPOF), but lowered the price target from $40 to $31.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:15 pm

ADTN

Needham analyst Ryan Koontz maintains a 'Buy' rating on Adtran (NASDAQ:ADTN) but has lowered the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:14 pm

DHI

Raymond James analyst Buck Horne has maintained an 'Outperform' rating on D.R. Horton (NYSE:DHI) but lowered the price target from $160 to $140.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:13 pm

CBAY

Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $33 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:11 pm

BCAB

HC Wainwright & Co. analyst Arthur He maintains a 'Buy' rating on BioAtla (NASDAQ:BCAB) but has lowered the price target from $17 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:11 pm

TYRA

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Tyra Biosciences (NASDAQ:TYRA) but lowers the price target from $20 to $19.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:09 pm

BMBL

Raymond James analyst Andrew Marok has maintained an 'Outperform' rating on Bumble (NASDAQ:BMBL), but lowered the price target from $22 to $17.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:04 pm

AXON

Raymond James analyst Brian Gesuale maintains an Outperform rating on Axon Enterprise (NASDAQ:AXON) and raises the price target from $223 to $233.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:03 pm

IOVA

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) but lowers the price target from $38 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:02 pm